1
TREATMENT OF CANCERS WITH IMMUNOSTIMULATORY HIV TAT DERIVATIVE POLYPEPTIDES. January 31, 2019: US20190030117-A1

Disclosed herein are compositions comprising a Human Immunodeficiency Virus (HIV) trans-activator of transcription (Tat) derivative polypeptide with increased immunostimulatory properties relative to the native Tat polypeptide, pharmaceutical compositions comprising the Tat derivative polypeptide, a ...


2
Multiplex MRM Assay for Evaluation of Cancer. January 31, 2019: US20190033320-A1

The current disclosure provides specific peptides, and derived ionization characteristics of the peptides from the estrogen receptor (ER), progesterone receptor (PR), and/or antigen Ki67 (Ki67) proteins that are particularly advantageous for quantifying the ER, PR, and/or Ki67 proteins directly in b ...


3
Delivery of Oligonucleotide-Functionalized Nanoparticles. January 31, 2019: US20190030185-A1

The present invention relates to compositions and methods for delivering an oligonucleotide-functionalized nanoparticle.


4
DELIVERY OF POLYNUCLEOTIDES USING RECOMBINANT AAV9. January 31, 2019: US20190030189-A1

The present invention relates to Adeno-associated virus 9 methods and materials useful for systemically delivering polynucleotides across the blood brain barrier. Accordingly, the present invention also relates to methods and materials useful for systemically delivering polynucleotides to the centra ...


5
Therapeutic Nanoparticles Having EGFR Ligands and Methods of Making and Using Same. Pfizer, January 31, 2019: US20190029960-A1

Provided herein in part is a therapeutic nanoparticle that includes a biocompatible polymer; a polymer-EGFR ligand conjugate, wherein the EGFR ligand is covalently bound directly or through a chemical linker to the polymer, and a therapeutic agent.


6
Biomarkers for Inflammatory Bowel Disease. January 31, 2019: US20190032140-A1

The present invention provides a method of assessing whether an individual is at high risk or low risk of inflammatory bowel disease (IBD) progression by determining the expression level of two or more genes in a whole blood sample. Also provided are methods for treating IBD in an individual who is ...


7
ANTIBODY-SN-38 IMMUNOCONJUGATES WITH A CL2A LINKER. January 31, 2019: US20190030175-A1

The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, w ...


8
DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER. January 31, 2019: US20190032150-A1

The present invention provides diagnostic and therapeutic methods and compositions for cancer. The invention provides methods of determining whether a patient having a cancer is likely to respond to treatment comprising a MAPK signaling inhibitor, methods of predicting responsiveness of a patient ha ...


9
METHODS FOR MONITORING AND TREATING CANCER. January 31, 2019: US20190032151-A1

The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, kidney cancer. The invention provides, inter alia, methods of treating cancer and methods of monitoring the response of a patient having a cancer to treatment with an anti-cancer therapy compr ...


10
Systems and methods for drone air traffic control utilizing geographic boundaries for management. January 31, 2019: US20190035285-A1

Systems and methods for drone air traffic control include, in an air traffic control system configured to manage Unmanned Aerial Vehicle (UAV) flight in a plurality of geographic regions, wherein the air traffic control system has one or more servers configured to manage each geographic region prede ...